Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Siglec-2

Siglec-2

Brief Information

Name:CD22
Target Synonym:B-Lymphocyte Cell Adhesion Molecule,SIGLEC2,BL-CAM,Siglec-2,Sialic Acid Binding Ig-like Lectin 2,B-cell receptor CD22,Sialic acid-binding Ig-like lectin 2,T-cell surface antigen Leu-14,CD22,CD22 Molecule,CD22 Antigen
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:40
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

SI2-HF2H6-Cell-based assay
Evaluation of CAR expression

293 cells were transfected with anti-CD22-scFv and RFP tag. 2e5 of the cells were stained with B. FITC-Labeled Human Siglec-2, His Tag (Cat. No. SI2-HF2H6, 10 µg/mL) and C. FITC-labeled Protein Control. A. Non-transfected 293 cells and C. FITC-labeled Protein Control were used as negative control. RFP was used to evaluate CAR (anti-CD22-scFv) expression and FITC was used to evaluate the binding activity of FITC-Labeled Human Siglec-2, His Tag (Cat. No. SI2-HF2H6) (QC tested).

SI2-H52H8-SPR
Human_FcRn_Heterodimer_Protein_SPR

Monoclonal Anti-Human Siglec-2 Antibody, Human IgG1 captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human Siglec-2 (176-687), His Tag (Cat. No. SI2-H52H8) with an affinity constant of 0.121 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).

SI2-H52H8-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Monoclonal Anti-Human CD22 Antibody, Human IgG1 on AHC Biosensor, can bind Human Siglec-2 / CD22 (176-687), His Tag (Cat. No. SI2-H52H8) with an affinity constant of 53 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name

CD22,SIGLEC2,BL-CAM,SIGLEC-2,Siglec2,SIGLEC2FLJ22814

Background

B-cell receptor CD22 is also known as Sialic acid-binding Ig-like lectin 2 (Siglec-2), B-lymphocyte cell adhesion molecule (BL-CAM), T-cell surface antigen Leu-14, which belongs to the immunoglobulin superfamily and SIGLEC (sialic acid binding Ig-like lectin) family. CD22 mediates B-cell B-cell interactions, and may be involved in the localization of B-cells in lymphoid tissues. Siglec-2 / CD22 binds sialylated glycoproteins, one of which is CD45. Siglec2 / CD22 plays a role in positive regulation through interaction with Src family tyrosine kinases and may also act as an inhibitory receptor by recruiting cytoplasmic phosphatases via their SH2 domains that block signal transduction through dephosphorylation of signaling molecules.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Moxetumomab pasudotox HA-22; GCR-8015; CAT-8015 Approved Astrazeneca Plc Lumoxiti United States Leukemia, Hairy Cell Innate Pharma 2018-09-13 Leukemia, Hairy Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Prolymphocytic; Leukemia, Lymphocytic, Chronic, B-Cell Details
Inotuzumab Ozogamicin WAY-207294; PF-5208773; CMC-544 Approved Pfizer Inc, Ucb Besponsa Mainland China Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Pfizer Investment Co Ltd 2017-06-28 Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Anti-CD19/22-CAR vector-transduced T cell therapy (Chinese PLA General Hospital) Phase 2 Clinical People'S Liberation Army General Hospital Military Service Leukemia; Lymphoma Details
Anti-CD22/CD19 monoclonal antibody-toxin conjugate Phase 1 Clinical Ut Southwestern Medical Center Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
UCART-22 UCART-22 Phase 1 Clinical Cellectis Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
CAR-20-19-22(Medical College of Wisconsin) CAR-20-19-22 The Medical College Of Wisconsin Nonprofit Details
RD-102 RD-102 Phase 1 Clinical Nanjing Iaso Biotherapeutics Co Ltd Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse Details
CD19-CD22 CAR-T cells (Shanghai Ultra-T Immune Therapeutics) Phase 1 Clinical Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CD22 CAR-T Cell Therapy (Hebei Senlang Biotechnology) Phase 1 Clinical Hebei Senlang Biological Technology Co Ltd Solid tumours; Sarcoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
GC-022 GC-022; GC-022F Phase 1 Clinical Gracell Biotechnologies (Shanghai) Co Ltd Leukemia, Lymphoid Details
Autologous CD19/CD22 chimeric antigen receptor T-cell therapy (MD Anderson Cancer Center) Phase 2 Clinical The University Of Texas MD Anderson Cancer Center Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Dual anti-CD19/CD22 CAR‐T cell therapy (B-cell malignancies, Stanford University) Phase 1 Clinical Stanford University Lymphoma, B-Cell Details
Anti-CD22 CAR-T cell therapy (iCarTAB BioMed) Phase 2 Clinical Aikangd Biomedical Technology (Suzhou) Co Ltd Lymphoma, B-Cell Details
Anti-CD22 CAR T cell therapy (Wuhan Bio-Raid) Phase 1 Clinical Wuhan Bio-Raid Biotechnology Lymphoma, B-Cell; Multiple Myeloma Details
Dual specificity CD19 and CD20 or CD22 CAR-T cell (Chinese PLA General Hospital) Phase 2 Clinical Pla General Hospital Leukemia; Lymphoma, B-Cell Details
Anti-CD22-CAR T cell therapy (Kecellitics Biotech) Phase 2 Clinical Kecellitics Biotech Company Ltd Leukemia; Lymphoma Details
Anti-CD19 anti-CD22 bispecific chimeric antigen receptor T cell therapy (Hrain Biotechnology) Phase 1 Clinical Hrain Biotechnology Leukemia, Lymphoid Details
Anti-CD22 CAR T cell therapy (Shanghai GeneChem) Phase 1 Clinical Shanghai Genechem Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
CART22-cells CART22-cells Phase 1 Clinical Novartis Pharma Ag, University Of Pennsylvania Leukemia; Lymphoma, B-Cell Details
CD22-targeted CAR-T cell therapy (PersonGen Biomedicine) Phase 1 Clinical Persongen Biotherapeutics Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Neoplasms, Plasma Cell Details
Anti-CD19 and anti-CD22 CAR T cell therapy (Seattle Children's Hospital) Phase 1 Clinical Seattle Children'S Hospital Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CD19x22 CAR T Cell Therapy (University Of Colorado Denver) Phase 1 Clinical University Of Colorado, Denver, Usa Lymphoma, Non-Hodgkin Details
Anti CD22 chimeric antigen receptor T cell therapy (Shanghai Yake Biotechnology) Phase 2 Clinical Shanghai YaKe Biotechnology Co Ltd, Beijing Boren Hospital, The First Affiliated Hospital Of Zhejiang University School Of Medicine Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CD19/CD20 Dual CAR-T Cell Therapy (China Immunotech) Phase 1 Clinical China Immunotech Co Ltd Lymphoma, Non-Hodgkin Details
TRPH-222 CD22-4AP; TRPH-222; CAT-02-106 Phase 1 Clinical Catalent Inc Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma; Lymphoma, Non-Hodgkin Details
4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) 4SCAR-T Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Neoplasms Details
CD19/CD22 bispecific CAR-T (Zhejiang University) Phase 2 Clinical Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19/CD22 chimeric antigen receptor T cell therapy (Nanjing Legend Biotech) LCAR-L10D Phase 1 Clinical Nanjing Legend Biotechnology Co Ltd, Second Affiliated Hospital Xi'An Jiaotong University Lymphoma, Large B-Cell, Diffuse Details
JCAR-018 JCAR-018 Phase 1 Clinical National Cancer Institute, Opus Bio Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
Epratuzumab AMG-412; CDP-3194; IMMU-103; IMMU-1903; IMMU-hLL2 Phase 3 Clinical Immunomedics Inc Lymphoma, B-Cell; Sjogren's Syndrome; Lupus Erythematosus, Systemic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
CD22-CART Phase 1 Clinical Hrain Biotechnology Co Ltd Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell Details
CD19/CD22 dual-target CAR-T cell therapy (Shenzhen University General Hospital) Phase 2 Clinical Shenzhen University General Hospital Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 and anti-CD22 CAR-T cell therapy(IASO Biotherapeutics) CT-120 Phase 2 Clinical Nanjing Iaso Biotherapeutics Co Ltd Lymphoma, B-Cell; Lymphoma, Non-Hodgkin Details
Epratuzumab-cys-tesirine ADCT-602 Phase 2 Clinical Adc Therapeutics Leukemia, Lymphoid Details
GTB-1550 DT-2219; OXS-1550; DT-2219ARL; IND-100780 Phase 2 Clinical University Of Minnesota Leukemia; Lymphoma, B-Cell Details
Anti-CD19/CD22 bispecific CAR-T cell therapy (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine) Phase 1 Clinical The Second Affiliated Hospital Of Henan University Of Traditional Chinese Medicine Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CD20/CD22 dual Targeted CAR T-cell therapy (Zhejiang University) Phase 1 Clinical Zhejiang University Hematologic Neoplasms Details
Anti-CD22 CAR-T cell therapy (No. 307 Hospital) Phase 2 Clinical The Fifth Medical Center Of Pla General Hospital (Formerly 307 Hospital) Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
AUTO-3 AUTO-3 Phase 2 Clinical University College London Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19/CD22 CAR-T cell therapy (Jiao Tong University) Phase 1 Clinical Shanghai Jiaotong University Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
ThisCAR-T-22(Fundamenta Therapeutics) ThisCAR-T-22 Phase 1 Clinical Lymphoma, B-Cell Details
Bispecific CD19/22 CAR T cells Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Details
anti-CD22-CAR-transduced T cells(Southwest Hospital) Phase 2 Clinical Southwest Hospital Leukemia; Lymphoma Details
4SCAR19/22 4SCAR19/22 Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Lymphoma, B-Cell; Leukemia, B-Cell Details
CD19/CD22 targeted CAR-T cells Clinical Shanghai YaKe Biotechnology Co Ltd Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
CTA-101 CTA-101 Phase 1 Clinical Nanjing Bioheng Biotech Co Ltd, Nanjing Medical University, Xuzhou Medical University (Xzmu) Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
IMJ-995 IMJ-995 Phase 1 Clinical Novartis Pharma Ag Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Suciraslimab SM-06; SM-03 Phase 3 Clinical Lonn Ryonn Pharma Ltd, Sinomab Bioscience Ltd Arthritis, Rheumatoid; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin Details
Chimeric antigen receptor T cell therapeutics (targeted CD19/CD20/CD22/CD30,Shanghai Unicar-Therapy Bio-medicine) Phase 2 Clinical Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message